Dr. Magdalene Moran is the Chief Scientific Officer, leading research and development at Rheostat Therapeutics. She received her PhD in 2002 from the Laboratory of Dr. David Clapham in the Program in Neuroscience at Harvard University, where she studied transcriptional regulation and cloned several novel ion channels (CatSpers 3 and 4, the voltage-gated channel Hv1, and TRPV3).
For the past 15 years, Dr. Moran has led drug discovery efforts on ion channels. This work elucidated the role of TRPA1 in cold hypersensitivity and helped define the function of TRPC4/5 - containing ion channels in anxiety and depression. The team she led identified six development candidates in the last six years and three molecules that entered human clinical trials for pain or CNS disorders.
Dr. Moran is the inventor on more than 50 published patent applications and issued patents directed at ion channel modulators.